Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 7/20 | 0.55 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | PRCP | P42785 | 1/20 | 0.46 |
| ▸ | BPTF | Q12830 | 2/20 | 0.45 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.45 |
| ▸ | AXL | P30530 | 3/20 | 0.44 |
| ▸ | TYRO3 | Q06418 | 3/20 | 0.44 |
| ▸ | MERTK | Q12866 | 3/20 | 0.44 |
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20294456 | 0.81 | CD274 (0.80) | CD274PRCPPDCD1ASIC3 | |
| SCHEMBL24865355 | 0.76 | PNMT (0.53) | BPTFAXLTYRO3MERTKASIC3 | |
| SCHEMBL22866959 | 0.74 | CD274 (0.86) | CD274ASIC3 | |
| SCHEMBL31576661 | 0.74 | CD274 (0.68) | CD274PRCPPDCD1ASIC3 | |
| SCHEMBL20294439 | 0.73 | CD274 (0.40) | CD274ADRA2AHTR7ADRA1APDCD1 | |
| SCHEMBL2804700 | 0.71 | MEN1 (0.58) | — | |
| SCHEMBL13757750 | 0.71 | HTR6 (0.58) | CD274PRCP | |
| SCHEMBL16554969 | 0.71 | CD274 (1.00) | CD274 | |
| SCHEMBL22807512 | 0.71 | CD274 (1.00) | CD274PRCPPDCD1ASIC3 | |
| SCHEMBL21625849 | 0.71 | NPC1 (0.44) | ADRA2ABPTF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226062-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2023-07-20 | — | — | US | claimed |
| US-20180177784-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2018-06-28 | — | — | US | claimed |
| WO-2018119263-A1 | HETEROCYCLIC COMPOUNDS DERIVATIVES AS PD-L1 INTERNALIZATION INDUCERS | INCYTE CORPORATION (US) | 2018-06-28 | — | — | WO | claimed |
| US-20230226062-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2023-07-20 | — | — | US | disclosed |
| US-20230226062-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2023-07-20 | — | — | US | disclosed |
| US-20180177784-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2018-06-28 | — | — | US | disclosed |
| US-20180177784-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2018-06-28 | — | — | US | disclosed |
| WO-2018119263-A1 | HETEROCYCLIC COMPOUNDS DERIVATIVES AS PD-L1 INTERNALIZATION INDUCERS | INCYTE CORPORATION (US) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018119263-A1 | HETEROCYCLIC COMPOUNDS DERIVATIVES AS PD-L1 INTERNALIZATION INDUCERS | INCYTE CORPORATION (US) | 2018-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180177784-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD274, PDCD1, PDCD1LG2 | CD274 1/4885ADRA2A 2829/4885HTR7 4103/4885 |
| US-20230226062-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD274, PDCD1, PDCD1LG2 | CD274 1/4885ADRA2A 2829/4885HTR7 4103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.